Coronary Artery Disease Clinical Trial
Official title:
Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD)
Omacor®/Lovaza® is an effective, and very safe mix of PO-3A, and the drug is currently
approved by the Federal authorities for the drug management of post-infarction patients with
high blood triglycerides. Given the growing length of CAD progression, it is pertinent that
many more patients will yield extra benefit from Lovaza® on top of aggressive antiplatelet
regimens and statin due to severity of their vascular disease. Therefore, mild antiplatelet
properties of PO-3A will be a highly desirable and attractive commodity of this medication.
The investigators believe that Omacor®/Lovaza® is ideally positioned for the chronic
management of CAD as a safe, efficient, and "gentle" agent with no harmful interactions with
statins or aspirin.
The investigators hypothesize that addition of Omacor may add mild antiplatelet protection
for CAD patients.
The study objectives are:
- To assess the ex vivo effects of Omacor® on platelet function in patients with coronary
artery disease (CAD).
- To compare ex vivo platelet-related effects after 7 and 14 days of therapy with Omacor
and statin combination versus statin alone in patients with chronic stable coronary
heart disease.
- To establish the relation of changes in platelet activity (if any) with the lipid
profile to prove an additional benefit of Omacor® on top of statin and aspirin.
In terms of incidence, prevalence, morbidity, and economic costs, coronary artery disease
represents a number 1 public health concern. Omacor®/Lovaza® is an effective, and very safe
mix of PO-3A, and the drug is currently approved by the Federal authorities for the drug
management of post-infarction patients with high blood triglycerides. Despite significant
progress in the prevention and treatment of vascular disease in the Western World in the
past two decades, national statistics indicate that the incidence and prevalence of heart
disease has been increasing steadily. Given the growing length of CAD progression, it is
pertinent that many more patients will yield extra benefit from Lovaza® on top of aggressive
antiplatelet regimens and statin due to severity of their vascular disease. Therefore, mild
antiplatelet properties of PO-3A will be a highly desirable and attractive commodity of this
medication.
We believe that Omacor®/Lovaza® is ideally positioned for the chronic management of CAD as a
safe, efficient, and "gentle" agent with no harmful interactions with statins or aspirin.
Also considering low clinical incidence of aspirin-induced interactions with other classes
of drugs, Lovaza® may fit nicely into a standard cocktail for diabetes, hypertension,
depression, arrhythmias, and heart failure management of CAD patients, which will expand the
drug utilization. However, platelet-related effects of Lovaza® on top of aspirin and statin
in patients with stable coronary disease are not known, but may be important due to the high
incidence of aspirin resistance and heavy burden of thrombin activation in such patients. We
have a large pool of patients with documented CAD (300-350/annum), and we will be able to
enroll relatively large amount of quality patients fast.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
| Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
| Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
| Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
| Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
| Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
| Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
| Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
| Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
| Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
| Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
| Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
| Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
| Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
| Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
| Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |